11-18-2013

Cyclometalated Iridium(III) Complexes with Deoxyribose Substituents

Ayan Maity
Case Western Reserve University

Jung-Suk Choi
Cleveland State University, J.CHOI43@csuohio.edu

Thomas S. Teets
Massachusetts Institute of Technology

Nihal Deligonul
Case Western Reserve University

Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub

Anthony J. Berdis
Cleveland State University, A.BERDIS@csuohio.edu

Part of the [Chemistry Commons](#)
How does access to this work benefit you? Let us know!

Publisher's Statement

See next page for additional authors
This is the accepted version of the following article: Maity, A.; Choi, J.; Teets, T. S.; Deligonul, N.; Berdis, A. J.; Gray, T. G. Cyclometalated Iridium(III) Complexes with Deoxyribose Substituents. *Chemistry – A European Journal* 2013, 19, 15924-15932., which has been published in final form at <http://onlinelibrary.wiley.com/doi/10.1002/chem.201301776/full>

Recommended Citation

Maity, Ayan; Choi, Jung-Suk; Teets, Thomas S.; Deligonul, Nihal; Berdis, Anthony J.; and Gray, Thomas G., "Cyclometalated Iridium(III) Complexes with Deoxyribose Substituents" (2013). *Chemistry Faculty Publications*. 173.
https://engagedscholarship.csuohio.edu/scichem_facpub/173

This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU. It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

Authors

Ayan Maity, Jung-Suk Choi, Thomas S. Teets, Nihal Deligonul, Anthony J. Berdis, and Thomas G. Gray

Cyclometalated Iridium(III) Complexes with Deoxyribose Substituents

Ayan Maity, Jung-Suk Choi, Thomas S. Teets, Nihal Deligonul,
Anthony J. Berdis, and Thomas G. Gray

Abstract: Fundamental study of enzymatic nucleoside transport suffers for lack of optical probes that can be tracked noninvasively. Nucleoside transporters are integral membrane glycoproteins that mediate the salvage of nucleosides and their passage across cell membranes. The substrate recognition site is the deoxyribose sugar, often with little distinction among nucleobases.

es. Reported here are nucleoside analogues in which emissive, cyclometalated iridium(III) complexes are “clicked” to C 1 of deoxyribose in place of canonical nucleobases. The resulting com-

Keywords: click chemistry • fluorescent probes • iridium • metalation • nucleobases

plexes show visible luminescence at room temperature and 77 K with microsecond length triplet lifetimes. A representative complex is crystallographically characterized. Transport and luminescence are demonstrated in cultured human carcinoma (KB3 1) cells.

Introduction

Iridium(III) has gained prominence in cell biology for luminescence tagging. Cyclometalated complexes of iridium(III) are rugged, coordinatively saturated organometallics that withstand the inhospitable settings of living cells.^[1–11] These complexes are high yielding phosphorescence lumophores that emit visible light across a range of wavelengths. Triplet luminescence arises from either a metal to ligand charge transfer (MLCT) state or a ligand centered excited state.^[12–21] Emission wavelengths are subject to rational tuning.^[22–27] The complexes’ excited state properties make them light emitting beacons; their ground state attributes suggest them for experiments in cells.^[28–34]

Cyclometalated iridium(III) complexes accommodate the standard techniques of bioconjugation. Reports of their attachment to biologically relevant molecules are legion.^[35] Complexes have been tethered to biotin for binding and crosslinking streptavidin.^[36,37] Iridium(III) complexes have also been attached to steroids, such as estradiol.^[38] Lo and co-workers report that emission of two distinct iridium complexes tethered to estradiol intensifies upon binding to the

receptor ER α .^[39] Sugars have been conjugated to iridium complexes indirectly through tethers that end in amino oxy moieties.^[40] These functional groups undergo bioconjugation reactions with the carbonyl groups of reducing sugars. The resulting complexes enter HeLa cells, and perinuclear staining occurs. Internalization is rapid for the glucose conjugate and less so for those of galactose, lactose, or maltose.

Nucleoside transporters are integral membrane glycoproteins.^[41] These proteins regulate cellular proliferation, neuro transmission, and cardiovascular activity by mediating the passage of natural and synthetic nucleosides both in and out of mammalian cells. They are imperfectly understood, despite being essential to cell survival and proliferation. In cells actively dividing, de novo nucleoside synthesis predominates. In other cells, nucleosides are recycled, and nucleoside transporters enable salvaging. There are two broad classes of transporters: equilibrative nucleoside transporters (ENT) and concentrative nucleoside transporters (CNT). The equilibrative transporters move nucleosides into or out of the cell, along a concentration gradient. Concentrative nucleoside transporters ferry nucleosides inwards, against the gradient. For most CNTs, nucleoside transport is coupled to Na⁺ transport, and these proteins are sodium nucleoside symporters. Another isoform, designated CNT3, utilizes Na⁺ and/or H⁺ to facilitate nucleoside transport.^[42]

Many chemotherapeutic drugs are nucleoside analogues,^[43–51] and their effectiveness depends on nucleoside transporters for cellular uptake. Mechanistic understanding of these glycoproteins is sparse, mainly because of limited structural information on such dynamic biomolecules. To date, there is a single report of a crystal structure of a CNT from the bacterium *Vibrio cholera*.^[52] Although more structures are likely to emerge, there is a clear need for probes that accurately report on the activity of transporters in cells and live animals.

This work reports optical markers for the facilitated diffusion of nucleosides. Nucleoside transporters recognize the sugar moiety; the nucleobase is secondary. We describe iridium(III) based emitters bound covalently to deoxyribose sugars through β glycoside linkages. These non natural nucleosides assemble in copper catalyzed [3+2] cycloaddition reactions of azides with terminal alkyne precursors. Metallation follows in thermal reactions with iridium(III) dimers.^[53] Instead of a nucleobase, the deoxyribose sugar supports cyclometalated iridium(III) at the 1' position. The new probes are visible light emitters. Their syntheses and optical properties are disclosed, along with crystallographic findings, cellular experiments, and density functional theory calculations of a representative complex.

Results and Discussion

Synthesis: Synthesis of a chelating deoxyribose ligand proceeded as in Scheme 1. Concentrated hydrochloric acid (1.5 equiv) was treated with 2 deoxy D ribose in methanol.

Scheme 1. Synthesis of nucleoside **7**.

The methyl protected product **2** was treated with *para* toluyl chloride in pyridine to protect the 3' and 5' hydroxyls. Compound **3** was converted to chloro Hoffer sugar **4** with an HCl solution in glacial acetic acid generated by adding acetyl chloride to an aqueous solution of acetic acid. The chloro sugar dissolved in *N,N* dimethylformamide was treated with sodium azide to yield the two anomers, α and β , of protected azido sugar **5**. The resulting diastereomeric mixture was separated by silica gel column chromatography. Deprotection with sodium methoxide in dry methanol afforded azidodeoxyribose **6**. Copper catalyzed [3+2] cycloaddition with 2 ethynylpyridine produced **7** after purification

by silica gel column chromatography. Ligand **7** recurs in all complexes in this work.^[54–56]

Metallonucleosides were prepared by the treatment of **7** with known, chloro bridged iridium(III) dimers. An example appears in Scheme 2. Ambient workup and precipitation yielded the products as analytically pure solids in isolated yields ranging from 62–79%. Scheme 3 enumerates the non nucleoside ligands.

Scheme 2. Synthesis of a typical iridium(III) metallonucleoside.

Scheme 3. Cyclometalating ligands.

Vapor diffusion of pentane into a chloroform solution afforded diffraction quality single crystals of $[\text{Ir}(\text{ppy})_2(\textbf{7})](\text{PF}_6)$. A thermal ellipsoid depiction appears in Figure 1. Iridium carbon bond lengths are 2.017(4) and 2.019(7) Å; the nucleoside pyridyl and triazolyl nitrogen donors exert similar *trans* influences. Iridium pyridyl nitrogen bond lengths are 2.047(5) and 2.048(6) Å for the 2 phenylpyridine ligands, and 2.163(5) Å for the nucleoside. The Ir–N_{triazolyl} distance is 2.141(4) Å, also reflecting a *trans* disposition to carbon. Counterion and intraligand metrics, including those of the sugar, are unexceptional.

New complexes were characterized by absorption and luminescence spectroscopies. Absorption features appear in the visible region from about 250–435 nm, with more intense bands in the ultraviolet. The weaker, longer wavelength features have been ascribed to spin allowed and spin forbidden metal to ligand charge transfer (MLCT) transitions,^[57] and the more intense bands of shorter wavelength to ligand $\pi^* \leftarrow \pi$ transitions. Such absorption features are common place among C^N chelated complexes of iridium(III).^[58]

Luminescence: The new complexes emit in fluid solution and in low temperature glasses. Normalized emission spectra at 77 K appear in Figure 2; emission maxima and life times are gathered in Table 1. The cyclometalating ligands modulate the luminescence; emission colors span the visible

Figure 1. Thermal ellipsoid representation (50% probability) of the cation of $[\text{Ir}(\text{ppy})_2(\mathbf{7})](\text{PF}_6)$ (**8**) along *c*. Hydrogen atoms and counterion are omitted for clarity. A partial atom labeling scheme is indicated. Selected interatomic distances [Å]: Ir1 C34, 2.017(4); Ir1 C23, 2.019(7); Ir1 N6, 2.047(5); Ir1 N5, 2.048(6); Ir1 N1, 2.141(4); Ir1 N4, 2.163(5). Selected angles [°]: N1 Ir1 N4, 76.7(3); C23 Ir1 N5, 80.2(3).

Figure 2. Normalized emission spectra (77 K) of new complexes in 2-methyltetrahydrofuran glass.

Table 1. Emission wavelengths (λ_{em}), lifetimes (τ), and quantum yields (ϕ_{em}) of iridium(III) complexes as PF_6 salts at 295 and 77 K in 2-methyltetrahydrofuran.

Sample	295 K			77 K	
	λ_{em} [nm]	τ [μs]	$\phi_{\text{em}}^{\text{[a]}}$	λ_{em} [nm]	τ [μs]
$[\text{Ir}(\text{ppy})_2(\mathbf{7})]^+$	475	1.5	0.15	475	4.4
$[\text{Ir}(\text{tpy})_2(\mathbf{7})]^+$	475	1.6	0.13	475	5.8
$[\text{Ir}(\text{bzq})_2(\mathbf{7})]^+$	520	6.8	0.026	500	62
$[\text{Ir}(\text{btp})_2(\mathbf{7})]^+$	592	7.2	0.044	582	13
$[\text{Ir}(\text{pq})_2(\mathbf{7})]^+$	565	1.2	0.064	542	4.6

[a] $\pm 10\%$; absorbance of solutions was ≤ 0.1 .

spectrum. Vibronic structure is pronounced. Their microsecond scale emission lifetimes indicate phosphorescence.

Taken together, the spectra indicate emitting states of considerable ligand character, with origins that range from $^3\text{MLCT}$ to ligand centered.

Calculations: The complex $[\text{Ir}(\text{btp})_2(\mathbf{7})]^+$ was selected for density functional theory calculations because of its long wavelength emission, which minimizes interference from cellular autofluorescence. A frontier Kohn Sham orbital energy level diagram is shown in Figure 3a with selected orbital depictions in Figure 3b. The highest occupied Kohn

Figure 3. a) Frontier Kohn Sham orbital energy level diagram of $[\text{Ir}(\text{btp})_2(\mathbf{7})]^+$. Continuum water solvation is included. b) Plots of selected orbitals (isodensity level is 0.03 a.u.). A color depiction of this Figure appears as the Supporting Information.

Sham orbital (HOMO) is delocalized over iridium (20%) and the cyclometalating btp ligands (79%); percentages are of electron density as calculated by a Mulliken population analysis.^[59] The lowest unoccupied Kohn Sham orbital (LUMO) concentrates (91%) on the pyridyl triazolyl arm. Because the LUMO resides on the ancillary (pyridyl triazolyl) ligand, the red shifted absorption profile is attributable to high energy, occupied btp π orbitals.

Cellular uptake of 8: Transport of compound **8** into KB3-1 cells was evaluated using fluorescence microscopy analysis.

In these experiments, human epidermal carcinoma cells, KB3 1, were treated with a fixed concentration (50 μM) of **8**, and images of treated cells were taken at variable time points using an excitation wavelength of 315 nm and an emission wavelength of 510 nm. To provide higher quality images, cells were also stained with Hoechst 33342 to stain their nuclei, which appeared blue (excitation wavelength of 340 nm and an emission wavelength of 480 nm). Images provided in Figure 4a show an increase in green fluorescence signal that, in some cases, appears to co-localize with the nuclei. In addition, the increase in green fluorescence signal that reflects intracellular accumulation of **8** in KB3 1 cells occurs in a time dependent manner, reaching a maximal amount in 24 h.

The dose dependency of the uptake of **8** was similarly evaluated. In these experiments, KB3 1 cells were treated

the fluorescent analogue. This nucleoside acts as a substrate for all nucleoside transporters, including hENT and hCNT family members,^[60–65] and should thus function as a broad spectrum inhibitor for the uptake of **8**. Cells were treated with DMSO (vehicle) or 2' deoxyadenosine (10 or 200 μM) for 24 h prior to treatment with 10 or 50 μM of compound **8**. Data provided in Figure 5 show that the inclusion of 10 μM 2' deoxyadenosine exerts little effect on the uptake of either low (10 μM) or high (50 μM) concentrations of **8**. In contrast, pretreatment with 200 μM 2' deoxyadenosine attenuates the phosphorescence signal caused by the uptake of **8**. The ability of high concentrations of 2' deoxyadenosine to block uptake suggests that the transport of **8** is catalyzed by one or more hENT family members. This suggestion is based on the fact that hENT family members have weaker affinity for natural nucleosides, such as 2 deoxyadenosine, compared to hCNTs.^[66,67]

The accumulation of **8** in KB3 1 cells was also quantified using a plate reader assay. KB3 1 cells were seeded onto 12 well plates at a density of 200000 cells per well. After overnight incubation to allow cell attachment, the cells were treated with variable concentrations of **8** for an additional 48 h. After 48 h, the medium containing **8** was removed, and the cells were washed twice with 200 μL of phosphate buffered saline (PBS). Each washing step was performed for 10 min at 37°C. All washes were collected and analyzed as described in the Experimental

Figure 4. a) Time dependent accumulation of **8** into human epidermal carcinoma cell lines, KB3 1. Images of cells treated with 50 μM of **8** were taken 4, 8, 12, and 24 h post treatment. b) Dose dependent accumulation of **8** into KB3 1 cells. Cells were incubated with 10 and 50 μM of **8** for 24 h. Compound **8** shows green fluorescence whereas the nuclei are stained with Hoechst 33342 (blue). Scale bars (100 μm) are provided for reference.

with variable concentrations of compound **8** for a fixed time interval (24 h). Representative data in Figure 4b show that KB3 1 cells treated with 50 μM **8** show more intense phosphorescence than cells treated with 10 μM **8**. As before, the higher emission intensity reflects intracellular accumulation of **8** that occurs in a dose dependent manner.

We next evaluated if the uptake of **8** occurs by passive diffusion or by the activity of one or more nucleoside transporters. This was accomplished by quantifying the ability of the natural nucleoside, 2' deoxyadenosine, to block the uptake of

Figure 5. The uptake of **8** is dependent on nucleoside transporter activity. KB3 1 cells were treated with variable concentration of **8** (10 and 50 μM) in the absence and presence of increasing concentrations of 2' deoxyadenosine. Cell images were taken after 24 h of exposure to **8**. Compound **8** shows green fluorescence whereas nuclei are stained with Hoechst 33342 (blue). Scale bars (100 μm) are provided for reference.

Section to measure the concentration of unbound **8**. The cells were then treated with 0.25 % trypsin and harvested by centrifugation. The supernatant was removed, and the cells were again washed with 1 mL of PBS at 37 °C to remove unbound and bound nucleoside. After this last wash step, the cells were lysed using 0.1 % Triton X 100 in 1×PBS. The amount of **8** present in the lysate was then measured using a fluorescent plate reader ($\lambda_{\text{ex}} = 340 \text{ nm}/\lambda_{\text{em}} = 480 \text{ nm}$). The data provided in Figure 6 show a dependency on the fluorescence signal as a function of the concentration of **8**, thus validating that **8** accumulates inside KB3 1 cells.

Figure 6. Quantifying the cellular accumulation of compound **8** in KB3 1 cells. Cells were treated with variable concentrations of **8** for 48 h and the fluorescence intensities of lysed cells were measured with a fluorescence plate reader. Data points for lysed KB3 1 cells are provided as circles and data points for the collected supernatants are provided as squares. These experiments represent an average of three or four independent experiments performed on different days. The error bars represent standard deviations.

Conclusion

Described herein is a synthetic strategy with which deoxyribose sugars are linked to chelating pyridyl triazoles. An efficient method has been developed that attaches these sugar bearing ligands to cyclometalated iridium(III). The resulting assemblies are luminescent. Choice of the cyclometalating C[^]N ligand controls emission colors, and lumophores of many hues can be prepared.

Membrane bound enzymes translocate nucleosides from extracellular space into the cytosol in the first step of nucleoside metabolism. Most nucleoside transport enzymes support sweeping variations in the nucleobase. The pendant (deoxy)sugar is the recognition site of nucleoside substrates. Chemical tags that monitor nucleoside transport are few, and studies of transport in vivo are hindered. The conjugates herein join an emissive complex to a deoxyribose sugar. They are potential photoactive surrogates of natural nucleosides; their biodisposition can be tracked optically. These studies are in progress.

Experimental Section

Materials and methods: Experimental procedures involving air or moisture sensitive substances were performed under argon using either Schlenk line techniques or in a nitrogen filled MBraun drybox. Anhydrous solvents were used directly from an MBraun solvent purification system or were purchased from Sigma Aldrich. ¹H NMR experiments were performed on a Varian 400 FT NMR spectrometer operating at 399.7 MHz. ¹H chemical shifts are reported in parts per million (δ), measured from tetramethylsilane (0 ppm) and are referenced to residual solvent in CDCl₃ (7.26 ppm), [D₆]acetone (2.05 ppm) or CD₂Cl₂ (5.32 ppm) for ¹H NMR. ¹³C{¹H} NMR spectra were recorded on a Varian INOVA AS 600 spectrometer operating at 150.0 Hz. ¹³C NMR chemical shifts are reported in parts per million (δ), measured from tetramethylsilane (0 ppm) and are referenced to solvent residuals in CDCl₃ (77.00 ppm) or CD₂Cl₂ (54.00 ppm). The configuration of the nucleoside was confirmed by ¹H NMR NOE difference spectroscopy on a Varian INOVA AS 600 instrument. High resolution electrospray ionization mass spectrometry (Hi Res ESI MS) experiments were performed on an IonSpec HiRes ESI FTICRMS at the University of Cincinnati Mass Spectrometry facility. Solvents were degassed by bubbling argon for 20 min prior to use for UV/Vis and luminescence measurements. UV/Vis and luminescence data were recorded using a Cary 5G UV/Vis/NIR spectrometer and a Cary Eclipse spectrometer, respectively. Thin layer chromatography (TLC) was carried out using Whatman silica gel UV254 plates. Column chromatography was performed using Fisher Scientific silica gel, sizes 32–63. Elemental analyses were carried out by Robertson Microlit Laboratories, Ledgewood, NJ.

Chemicals from commercial sources were used as received. 2 Deoxy D ribose, pyridine, *p* toluoyl chloride, acetyl chloride, 2 ethoxyethanol, and sodium methoxide (NaOMe) were purchased from Acros Organics. Sodium azide (NaN₃), *N,N* diisopropylethylamine (DIPEA) and copper(I) iodide (CuI) were purchased from Sigma Aldrich. Iridium(III) chloride (IrCl₃·3H₂O) and ammonium hexafluorophosphate (NH₄PF₆) were purchased from Strem Chemicals.

Hoffer's α chlorosugar (1 α chloro 3,5 di (*O p* toluoyl) 2 deoxy D ribose) was synthesized with a slight modification of the first step of an established procedure^[68] in which an equivalent amount of concentrated hydrochloric acid was used in place of dissolving hydrogen chloride gas in methanol. Cyclometalated Ir^{III} μ chloro bridged dimers, (C[^]N)₂Ir(μ Cl)₂Ir(C[^]N)₂ (abbreviated as [(Ir(C[^]N)₂(μ Cl)₂)]₂), were synthesized with the method reported by Nonoyama;^[69] IrCl₃·3H₂O was refluxed with 2.5 equiv cyclometalating ligand in a 3:1 mixture of 2 ethoxyethanol and water. Synthesis and characterization of [(Ir(ppy)₂(μ Cl)₂)]₂,^[70] [(Ir(tpy)₂(μ Cl)₂)]₂,^[71] [(Ir(bzq)₂(μ Cl)₂)]₂,^[72] [(Ir(pq)₂(μ Cl)₂)]₂,^[73] and [(Ir(btp)₂(μ Cl)₂)]₂^[74] were reported previously.

1-β-Azido-3,5-di-(*O-p*-toluoyl)-2-deoxy-D-ribose (5β): NaN₃ (0.390 g, 5.99 mmol) was added to a mixture of α chlorosugar **4** (1.50 g, 3.85 mmol) in dry DMF (50 mL), stirred at RT for 30 min. The mixture was vigorously stirred at RT for 2 h in an inert atmosphere as the reaction was tracked by TLC. After completion of the reaction, EtOAc (100 mL) was added to the mixture to form a uniform organic layer. The organic layer was washed with water (2×100 mL) followed by brine (150 mL) and dried (over anhydrous Na₂SO₄). Evaporation under reduced pressure afforded the crude product mixture (1.4 g, 92 %, β/α ≈ 1:1), which was resolved by chromatography using diethyl ether/hexanes (1:9 v/v) mixture. Compound **5β** was eluted as the first fraction. Yield: 0.823 g (54 %); *R*_f=β: 0.55 (diethyl ether/hexanes=30:70); ¹H NMR (400 MHz, CDCl₃): δ = 7.97 (d, 2H, *J*=8.1 Hz), 7.89 (d, 2H, *J*=8.2 Hz), 7.24–7.21 (m, 4H), 5.70 (t, 1H, *J*=5.2 Hz), 5.56 (td, 1H, *J*=5.5, 2.4 Hz), 4.59–4.50 (m, 3H), 2.42–2.39 ppm (m, 8H); HRMS: calcd for C₂₁H₂₁N₃NaO₅ [*M*+Na]⁺: 418.1379; found: 418.1376.

1-α-Azido-3,5-di-(*O-p*-toluoyl)-2-deoxy-D-ribose (5α): Collected as the second fraction from the column. Yield: 0.7 g (46 %); *R*_f=α: 0.48 (diethyl ether/hexanes=30:70); ¹H NMR (400 MHz, CDCl₃): δ = 7.96 (d, 2H, *J*=8.3 Hz), 7.91 (d, 2H, *J*=8.2 Hz), 7.27–7.23 (m, 4H), 5.71 (d, 1H, *J*=5.6 Hz), 5.51–5.48 (m, 1H), 4.72 (q, 1H, *J*=3.8 Hz), 4.63–4.50 (m, 2H),

2.58 2.52 (m, 1H), 2.42 (s, 3H), 2.41 (s, 3H), 2.25 2.21 ppm (m, 1H); HRMS: calcd for $C_{21}H_{21}N_3NaO_5$ $[M+Na]^+$: 418.1379; found: 418.1366.

1- β -Azido-2-deoxy-D-ribose (6): Dry MeOH (50 mL) followed by sodium methoxide (0.410 g, 7.58 mmol) were added to a dry round bottom flask loaded with **5 β** (0.950 g, 2.4 mmol). The reaction mixture was stirred under inert atmosphere at RT for 24 h and monitored by TLC. After this time, the solvent was removed under vacuum. The residue was loaded on a silica gel column, and the desired product **6** was isolated when eluted with 5% MeOH in diethyl ether. Yield: 0.310 g (81%); R_f =0.60 (methanol/diethyl ether=5:95); 1H NMR (400 MHz, $CDCl_3$): δ =5.55 (t, 1H, J =4.0 Hz), 4.39 (d, 1H, J =4.8 Hz), 3.95 3.92 (m, 1H), 3.75 3.66 (m, 2H), 2.15 2.11 ppm (m, 2H); HRMS: calcd for $C_5H_9N_3NaO_3$ $[M+Na]^+$: 182.0542; found: 182.0545.

1-(1'- β -2'-Deoxy-D-ribofuranosyl)-4-(5-(2-pyridinyl))-1,2,3-triazole (7): Compound **6** (0.540 g, 3.39 mmol) was dissolved in a mixture of THF (10 mL) and toluene (40 mL). 2 Ethynylpyridine (0.54 mL, 5.35 mmol), DIPEA (2.7 mL, 15.5 mmol), and CuI (0.646 g, 3.39 mmol) were added to the reaction mixture. The solution was heated to reflux. The reaction was complete after 24 h, as monitored by TLC. The solvent was removed by rotary evaporation. The crude reaction mixture was loaded on a silica gel column packed with 1:1 v/v diethyl ether/hexanes. The desired product **7** was isolated when the eluant polarity was increased to 1:9 v/v MeOH/diethyl ether. Yield: 0.665 g (75%); R_f =0.20 (methanol/diethyl ether=5:95); 1H NMR (400 MHz, $CDCl_3$): δ =8.49 (d, 1H, J =4.0 Hz), 8.46 (s, 1H), 8.09 (d, 1H, J =8.3 Hz), 7.77 (td, 1H, J =6.0, 1.6 Hz), 7.24 7.21 (m, 1H), 6.42 (t_{app} , characteristic peak for β anomer, 1H, J =6.7 Hz), 4.77 (d, 1H, J =4.8 Hz), 4.13 (d, 1H, J =3.9 Hz), 3.88 3.72 (m, 2H), 2.89 2.83 (m, 1H), 2.63 2.57 ppm (m, 1H); ^{13}C NMR (150 MHz, $CDCl_3$): δ =149.72, 149.23, 148.03, 137.24, 123.14, 121.53, 120.43, 88.96, 88.39, 71.69, 62.61, 41.67 ppm; HRMS: calcd for $C_{12}H_{14}N_4NaO_3$ $[M+Na]^+$: 285.0964; found: 285.0974; elemental analysis calcd for $C_{12}H_{14}N_4O_3$: C 54.96, H 5.38, N 21.36; found: C 55.12, H 5.42, N 21.34.

[Ir(ppy)₂](7)PF₆ (8): $[[Ir(ppy)_2(\mu Cl)]_2]$ (0.040 g, 0.037 mmol) was suspended in acetonitrile (20 mL). To this was added a 10 mL THF solution of compound **7** (0.024 g, 0.092 mmol) followed by NH_4PF_6 (0.012 g, 0.076 mmol). After being purged with argon, the reaction mixture was heated to 45°C and left to stir for 12 h. The reaction was complete after this time period as indicated by TLC. The solvent was removed under reduced pressure to render a dark orange residue. The crude reaction mixture was washed with THF, water, and ice cold acetone followed by diethyl ether and pentane. The product was vacuum dried to give analytically pure compound. Yield: 0.053 g (75%); 1H NMR (400 MHz, CD_2Cl_2): δ =9.23 (d, 1H, J =3.2 Hz), 8.25 (dd, 1H, J =5.0, 4.2 Hz), 8.01 (t, 1H, J =7.8 Hz), 7.95 7.92 (m, 2H), 7.83 (d, 1H, J =5.4 Hz), 7.81 7.76 (m, 2H), 7.72 7.68 (m, 3H), 7.50 (dd, 1H, J =6.3, 5.3 Hz), 7.29 (t, 1H, J =7.3 Hz), 7.10 6.96 (m, 4H), 6.92 (t, 1H, J =7.1 Hz), 6.86 (t, 1H, J =7.6 Hz), 6.50 6.41 (m, 1H), 6.31 6.28 (m, 2H), 4.73 4.62 (m, 1H), 4.12 4.08 (m, 1H), 3.96 3.80 (m, 2H), 2.76 2.53 ppm (m, 2H); ^{13}C NMR (150 MHz, CD_2Cl_2): δ =168.59, 167.95, 150.83, 150.04, 149.94, 149.82, 149.22, 149.07, 146.68, 144.56, 140.18, 138.71, 138.64, 132.50, 132.07, 131.12, 130.43, 127.13, 125.32, 124.92, 124.46, 124.36, 124.13, 124.00, 123.79, 123.69, 123.31, 122.86, 120.19, 91.88, 89.11, 70.97, 62.04, 42.82 ppm; UV/Vis (acetonitrile): λ_{max} (ϵ)=249 (27000), 380 nm (4000 $M^{-1}cm^{-1}$); emission (acetonitrile): λ_{ex} (Int.)=478 (190), 506 nm (178); HRMS: calcd for $C_{34}H_{30}IrN_6O_3$ $[M PF_6]^+$: 763.2003; found: 763.2004; elemental analysis calcd for $C_{34}H_{30}F_6IrN_6O_3P$: C 44.98, H 3.33, N 9.26; found: C 45.21, H 3.52, N 9.35.

[Ir(tpy)₂](7)PF₆: $[[Ir(tpy)_2(\mu Cl)]_2]$ (0.046 g, 0.041 mmol) was suspended in dry acetonitrile (25 mL). To this was added a solution of compound **7** (0.026 g, 0.099 mmol) dissolved in 10 mL dry THF, followed by NH_4PF_6 (0.014 g, 0.086 mmol). After being purged with argon, the reaction mixture was sealed and heated to 45°C. The reaction was complete after 12 h as indicated by TLC. The solvent was removed under reduced pressure to render a dark orange residue. The crude reaction mixture was washed with THF, water and ice cold acetone, followed by diethyl ether and pentane. The remaining product was dried under vacuum to give an analytically pure compound. Yield: 0.047 g (62%); 1H NMR (400 MHz, $[D_6]acetone$): δ =9.43 (d, 1H, J =5.9 Hz), 8.40 (dd, 1H, J =5.3, 3.2 Hz),

8.19 (t, 1H, J =7.8 Hz), 8.14 (d, 2H, J =8.3 Hz), 7.95 7.85 (m, 4H), 7.78 7.69 (m, 3H), 7.55 (t, 1H, J =5.6 Hz), 7.13 7.05 (m, 2H), 6.86 (d, 1H, J =7.4 Hz), 6.78 (d, 1H, J =7.5 Hz), 6.46 (q, 1H, J =8.8 Hz), 6.17 6.14 (m, 2H), 4.63 4.48 (m, 1H), 4.07 4.08 (m, 1H), 3.76 3.62 (m, 2H), 2.64 2.53 (m, 2H), 2.08 (s, 3H), 2.05 ppm (s, 3H); ^{13}C NMR (150 MHz, CD_2Cl_2): δ =168.56, 167.97, 150.83, 150.03, 149.92, 149.85, 149.19, 148.89, 146.81, 141.91, 141.84, 141.48, 140.69, 140.03, 138.51, 138.45, 133.19, 132.75, 127.03, 125.21, 124.82, 124.36, 124.29, 123.85, 123.67, 123.52, 123.39, 123.10, 119.79, 91.76, 89.10, 70.78, 61.92, 42.78, 22.05 ppm (2 CH_3 C); UV/Vis (acetonitrile): λ_{max} (ϵ)=249 (15000), 267 (sh, 14000), 378 nm (3000 $M^{-1}cm^{-1}$); emission (acetonitrile): λ_{ex} (Int.)=480 (160), 508 nm (147); HRMS: calcd for $C_{36}H_{34}IrN_6O_3$ $[M PF_6]^+$: 791.2316; found: 791.2320; elemental analysis calcd for $C_{36}H_{34}F_6IrN_6O_3P$: C 46.20, H 3.66, N 8.98; found: C 46.51, H 3.85, N 9.21.

[Ir(bzq)₂](7)PF₆: $[[Ir(bzq)_2(\mu Cl)]_2]$ (0.045 g, 0.038 mmol) was suspended in dry acetonitrile (20 mL). To this was added a 10 mL THF solution of compound **7** (0.025 g, 0.096 mmol) followed by NH_4PF_6 (0.016 g, 0.096 mmol). The reaction mixture was purged with argon, heated to 45°C, and left to stir for 12 h. The reaction was complete after this time period as indicated by TLC. The solvent was removed under reduced pressure to render a dark orange residue. The crude reaction mixture was washed with THF, water, and ice chilled methanol, followed by diethyl ether and pentane. The product was vacuum dried to give analytically pure compound. Yield: 0.058 g (79%); 1H NMR (400 MHz, CD_2Cl_2): δ =9.48 (d, 1H, J =13.7 Hz), 8.31 8.29 (m, 3H), 8.06 (ddd, 1H, J =8.9, 5.3, 1.2 Hz), 7.91 7.85 (m, 4H), 7.78 (t, 1H, J =6.5 Hz), 7.72 7.68 (m, 2H), 7.51 (d, 1H, J =7.6 Hz), 7.47 7.37 (m, 3H), 7.18 7.12 (m, 2H), 7.10 (td, 1H, J =7.2, 1.4 Hz), 6.40 6.24 (m, 3H), 4.79 4.62 (m, 1H), 3.98 3.94 (m, 1H), 3.85 3.82 (m, 2H), 2.70 2.36 ppm (m, 2H); ^{13}C NMR (150 MHz, CD_2Cl_2): δ =158.10, 157.52, 151.21, 150.41, 149.44, 149.06, 148.37, 148.13, 146.42, 143.19, 141.57, 141.32, 140.15, 137.70, 134.86, 134.56, 130.50, 130.39, 130.29, 129.83, 129.74, 129.41, 127.79, 126.92, 124.88, 124.44, 124.10, 123.85, 122.95, 122.74, 122.37, 121.30, 120.80, 91.60, 88.92, 69.79, 61.11, 42.43 ppm; UV/Vis (acetonitrile): λ_{max} (ϵ)=242 (14000), 315 nm (8000 $M^{-1}cm^{-1}$); emission (acetonitrile): λ_{ex} (Int.)=516 (176), 540 nm (sh, 150); HRMS: calcd for $C_{38}H_{30}IrN_6O_3$ $[M PF_6]^+$: 811.2003; found: 811.2004; elemental analysis calcd for $C_{38}H_{30}F_6IrN_6O_3P$: C 47.75, H 3.16, N 8.79; found: C 47.86, H 3.36, N 9.11.

[Ir(btp)₂](7)PF₆: $[[Ir(btp)_2(\mu Cl)]_2]$ (0.050 g, 0.038 mmol) was suspended in dry acetonitrile (25 mL). To this was added a solution of compound **7** (0.026 g, 0.098 mmol) in 10 mL dry THF, followed by NH_4PF_6 (0.014 g, 0.086 mmol). After being purged with argon, the reaction mixture was sealed and heated to 45°C. The reaction was complete after 12 h as indicated by TLC. The solvent was removed under reduced pressure to render a brick red residue. The crude reaction mixture was washed with THF, water and ice cold methanol, followed by diethyl ether and pentane. The remaining product was dried under vacuum to give analytically pure compound. Yield: 0.061 g (78%); 1H NMR (400 MHz, $[D_6]acetone$): δ =9.48 (d, 1H, J =9.0 Hz), 8.47 (d, 1H, J =5.6 Hz), 8.27 (d, 1H, J =6.3 Hz), 8.07 7.98 (m, 2H), 7.94 7.80 (m, 3H), 7.65 7.30 (m, 5H), 7.20 (dd, 2H, J =8.9, 6.3 Hz), 7.10 (t, 2H, J =6.4 Hz), 6.89 (dd, 2H, J =7.6, 6.1 Hz), 6.45 6.40 (m, 1H), 6.19 6.09 (m, 2H), 4.70 4.39 (m, 1H), 4.21 3.92 (m, 1H), 3.76 3.52 (m, 2H), 2.74 2.52 ppm (m, 2H); UV/Vis (acetonitrile): λ_{max} (ϵ)=283 (31000), 325 (20000), 435 nm (7500 $M^{-1}cm^{-1}$); emission (acetonitrile): λ_{ex} (Int.)=593 (180), 637 nm (126); HRMS: calcd for $C_{38}H_{30}IrN_6O_3S_2$ $[M PF_6]^+$: 875.1445; found: 875.1437; elemental analysis calcd for $C_{38}H_{30}F_6IrN_6O_3PS_2$: C 44.75, H 2.96, N 8.24; found: C 44.88, H 3.19, N 8.27.

[Ir(pq)₂](7)PF₆: $[[Ir(pq)_2(\mu Cl)]_2]$ (0.040 g, 0.031 mmol) was suspended in dry acetonitrile (20 mL). To this was added a solution of **7** in 10 mL dry THF, followed by NH_4PF_6 (0.013 g, 0.078 mmol). After being purged with argon, the reaction mixture was heated to 45°C and left to stir for 16 h. The reaction was complete after this time period as indicated by TLC. The solvent was removed under reduced pressure to render a dark orange residue. The crude reaction mixture was washed with THF, water and ice cold acetone followed by diethyl ether and pentane. The product was vacuum dried to give analytically pure compound. Yield: 0.048 g (76%); 1H NMR (400 MHz, CD_2Cl_2): δ =8.90 (m, 1H), 8.28 8.13 (m,

4H), 8.08 8.05 (m, 2H), 7.95 (q, 1H, $J=5.8$ Hz), 7.77 7.69 (m, 4H), 7.60 (q, 1H, $J=9.1$ Hz), 7.39 7.11 (m, 7H), 6.93 (q, 1H, $J=8.2$ Hz), 6.86 (q, 1H, $J=7.4$ Hz), 6.79 6.75 (m, 1H), 6.69 (d, 1H, $J=7.6$ Hz), 6.52 (dd, 1H, $J=8.5, 6.7$ Hz), 6.30 6.26 (m, 1H), 4.60 4.27 (m, 1H), 3.96 3.95 (m, 1H), 3.71 3.63 (m, 2H), 2.57 2.22 ppm (m, 2H); ^{13}C NMR (150 MHz, CD_2Cl_2): $\delta=171.10, 170.21, 151.59, 149.67, 148.51, 148.31, 148.08, 147.21, 146.88, 146.41, 140.43, 140.19, 139.85, 135.77, 134.94, 131.99, 131.76, 131.09, 130.59, 129.67, 129.32, 128.30, 128.03, 127.51, 127.37, 127.08, 126.97, 126.64, 126.03, 125.79, 125.25, 123.68, 123.57, 123.26, 123.05, 117.88, 117.80, 91.31, 89.11, 69.81, 61.48, 41.99$ ppm; UV/Vis (acetonitrile): $\lambda_{\text{max}}(\epsilon)=234$ (8200), 264 (7600), 332 nm ($4000 \text{ m}^{-1} \text{ cm}^{-1}$); emission (acetonitrile): $\lambda_{\text{ex}}(\text{Int.})=567$ nm (245); HRMS: calcd for $\text{C}_{42}\text{H}_{34}\text{IrN}_6\text{O}_3$ [$M + \text{PF}_6$] $^+$: 863.2322; found: 863.2328; elemental analysis calcd for $\text{C}_{42}\text{H}_{34}\text{F}_6\text{IrN}_6\text{O}_3\text{P}$: C 50.05, H 3.40, N 8.34; found: C 50.15, H 3.77, N 8.60.

Luminescence measurements: Steady state luminescence spectra were recorded at room temperature on a Cary Eclipse fluorescence spectrophotometer or on an automated Photon Technology International (PTI) QM 4 fluorimeter equipped with a 150 W Xe arc lamp and a Hamamatsu R928 photomultiplier tube. Excitation light was excluded with suitable glass filters. Sample solutions were added to a quartz ESR tube equipped with a Teflon valve, freeze pump thaw degassed (four cycles, 1×10^{-5} Torr), and sealed. Low temperature emission spectra were recorded in rigid solvent glass at 77 K by immersion of the sealed ESR tubes into a liquid nitrogen filled dewar. Time resolved phosphorescence lifetime data were recorded on a nanosecond laser system described previously.^[75]

Emission quantum yields ($23 \pm 2^\circ\text{C}$) were measured^[76] in deoxygenated 2-methyltetrahydrofuran by referencing sample luminescence intensities to those of optically dilute standards of 9,10-diphenylanthracene ($\phi_{\text{em}}=0.9$) in cyclohexane.^[77] Quantum yields, ϕ , were computed by using Equation (1):

$$\phi_s = \phi_r \left(\frac{A_r \eta_r^2 D_r}{A_s \eta_s^2 D_s} \right) \quad (1)$$

where r and s indicate reference and sample, respectively, A is the absorbance at wavelength λ_{exc} , η is the refractive index of the solvent, and D is the integrated area beneath the absorption spectrum.

Cell culture procedures: KB3 1 cells were cultured at 37°C in humidified air with 5% CO_2 and maintained in Dulbecco's modified Eagle's medium (Mediatech, VA) supplemented with 10% fetal bovine serum (USA Scientific), 100 U mL^{-1} penicillin (Invitrogen, NY), 100 $\mu\text{g mL}^{-1}$ streptomycin and 250 μL gentamicin. The doubling time for these cells is approximately 24 h. In cell based experiments, a fixed amount of compound **8** was dissolved in 100% DMSO to obtain a final stock concentration of 100 mM. Serial dilutions of compound **8** (10 0.01 mM) were then made from this stock solution using 100% DMSO as the co solvent.

Visualizing the cellular uptake of compound 8 by microscopy: The cellular uptake of compound **8** was visualized by microscope imaging of KB3 1 cells. Cells were plated on 35 mm glass bottom microwell dishes and pre incubated in the absence or presence of variable concentrations of 2'-deoxyadenosine. After 24 h, cells were treated with variable concentrations of compound **8** (0 200 μM) for time periods varying from 4 to 48 h. Cells were then washed twice with $1 \times \text{PBS}$, fixed with 4% paraformaldehyde, and washed twice with $1 \times \text{PBS}$. Images were obtained using a Nikon (TE 2000 S) microscope with UV lamp. Positive controls were obtained measuring cellular uptake of Hoechst 33342 at a final concentration of 5 $\mu\text{g mL}^{-1}$. For the detection of compound **8**, an excitation wavelength (λ_{ex}) of 365 nm and an emission wavelength (λ_{em}) of 477 nm were used.

Studies for the quantification of compound **8** were performed by seeding cells onto 12 well plates at a density of 200000 cells per well. After 24 h, cells were treated with variable concentrations of compound **8** (0 200 μM) for 24 48 h. Cells were treated with 0.25% trypsin and harvested by centrifugation. The supernatant was removed and then washed with PBS. Cells were lysed with 0.1% Triton X 100 in $1 \times \text{PBS}$ and then observed using a fluorescent plate reader ($\lambda_{\text{ex}}=340 \text{ nm}/\lambda_{\text{em}}=480 \text{ nm}$).

X-ray single crystal structure analysis: Single crystal X ray data were collected on a Bruker AXS SMART APEX CCD diffractometer using monochromatic $\text{Mo}_{\text{K}\alpha}$ radiation with the omega scan technique. The unit cells were determined using SMART^[78] and SAINT+.^[79] Data collection for all crystals was conducted at 100 K (173°C). All structures were solved by direct methods and refined by full matrix least squares against F^2 with all reflections using SHELXTL.^[80] Refinement of extinction coefficients was found to be insignificant. All non hydrogen atoms were refined anisotropically. Hydrogen atoms were placed in standard calculated positions and were refined with an isotropic displacement parameter 1.2 times that of the adjacent carbon or oxygen.

Computations: Spin restricted density functional theory calculations were executed with Gaussian09 (rev.A.02).^[81] Geometries were fully optimized. Calculations employed the exchange and correlation functionals of Perdew, Burke, and Ernzerhof,^[82] and the TZVP basis set. For iridium, the Stuttgart Dresden (SDD) effective core potential and basis set were used; scalar relativistic effects are included implicitly. Harmonic frequency calculations returned all real vibrational frequencies. The calculations, including geometry optimizations, impose continuum solvation in water, using the integral equation formalism of Tomasi's polarizable continuum model.^[83–86] Population analyses were performed with the AOMix CDA software of Gorelsky.^[87,88]

Acknowledgements

This research was supported by NSF grant CBET 1066107. We thank Professor D. G. Nocera (Harvard University) for access to instrumentation. T.S.T. acknowledges the Fannie and John Hertz Foundation for a graduate research fellowship. N.D. thanks the Republic of Turkey for a fellowship.

- [1] Y. Yang, Q. Zhao, W. Feng, F. Li, *Chem. Rev.* **2013**, *113*, 192–270.
- [2] F. L. Thorp Greenwood, *Organometallics* **2012**, *31*, 5686–5692.
- [3] M. Patra, G. Gasser, *ChemBioChem* **2012**, *13*, 1232–1252.
- [4] E. Baggeley, J. A. Weinstein, J. A. G. Williams, *Coord. Chem. Rev.* **2012**, *256*, 1762–1785.
- [5] F. L. Thorp Greenwood, R. G. Balasingham, M. P. Coogan, *J. Organomet. Chem.* **2012**, *714*, 12–21.
- [6] K. K. W. Lo, A. W. T. Choi, W. H. T. Law, *Dalton Trans.* **2012**, *41*, 6021–6047.
- [7] K. K. W. Lo, S. P. Y. Li, K. Y. Zhang, *New J. Chem.* **2011**, *35*, 265–287.
- [8] Q. Zhao, C. Huang, F. Li, *Chem. Soc. Rev.* **2011**, *40*, 2508–2524.
- [9] K. K. W. Lo, K. Y. Zhang, S. P. Y. Li, *Pure Appl. Chem.* **2011**, *83*, 823–840.
- [10] K. L. Haas, K. J. Franz, *Chem. Rev.* **2009**, *109*, 4921–4960.
- [11] A. Ruggi, D. N. Reinhoudt, A. H. Velders, in *Bioinorganic Medicinal Chemistry* (Ed.: E. Alessio), Wiley, New York **2011**, pp. 383–406.
- [12] S. Sprouse, K. A. King, P. J. Spellane, R. J. Watts, *J. Am. Chem. Soc.* **1984**, *106*, 6647–6653.
- [13] K. A. King, P. J. Spellane, R. J. Watts, *J. Am. Chem. Soc.* **1985**, *107*, 1431–1432.
- [14] Y. Ohsawa, S. Sprouse, K. A. King, M. K. DeArmond, K. W. Hanck, R. J. Watts, *J. Phys. Chem.* **1987**, *91*, 1047–1054.
- [15] K. Ichimura, T. Kobayashi, K. A. King, R. J. Watts, *J. Phys. Chem.* **1987**, *91*, 6104–6106.
- [16] F. O. Garces, K. A. King, R. J. Watts, *Inorg. Chem.* **1988**, *27*, 3464–3471.
- [17] F. O. Garces, R. J. Watts, *Inorg. Chem.* **1990**, *29*, 582–584.
- [18] K. Dedeian, P. I. Djurovich, F. O. Garces, G. Carlson, R. J. Watts, *Inorg. Chem.* **1991**, *30*, 1685–1687.
- [19] A. P. Wilde, K. A. King, R. J. Watts, *J. Phys. Chem.* **1991**, *95*, 629–634.
- [20] C. Ulbricht, B. Beyer, C. Friebe, A. Winter, U. S. Schubert, *Adv. Mater.* **2009**, *21*, 4418–4441.
- [21] H. Yersin, W. J. Finkenzeller, in *Highly Efficient OLEDs with Phosphorescent Materials* (Ed.: H. Yersin), Wiley VCH, Weinheim **2008**, pp. 1–97.

- [22] F. Neve, A. Crispini, S. Campagna, S. Serroni, *Inorg. Chem.* **1999**, *38*, 2250–2258.
- [23] A. B. Tamayo, S. Garon, T. Sajoto, P. I. Djurovich, I. M. Tsyba, R. Bau, M. E. Thompson, *Inorg. Chem.* **2005**, *44*, 8723–8732.
- [24] S. Stagni, S. Colella, A. Palazzi, G. Valenti, S. Zacchini, F. Paolucci, M. Marcaccio, R. Q. Albuquerque, L. De Cola, *Inorg. Chem.* **2008**, *47*, 10509–10521.
- [25] A. F. Rausch, M. E. Thompson, H. Yersin, *J. Phys. Chem. A* **2009**, *113*, 5927–5932.
- [26] N. M. Shavaleev, F. Monti, R. D. Costa, R. Scopelliti, H. J. Bolink, E. Ortí, G. Accorsi, N. Armaroli, E. Baranoff, M. Grätzel, M. K. Nazeeruddin, *Inorg. Chem.* **2012**, *51*, 2263–2271.
- [27] N. M. Shavaleev, F. Monti, R. Scopelliti, A. Baschieri, L. Sambri, N. Armaroli, M. Grätzel, M. K. Nazeeruddin, *Organometallics* **2013**, *32*, 460–467.
- [28] C. Li, M. Yu, Y. Sun, Y. Wu, C. Huang, F. Li, *J. Am. Chem. Soc.* **2011**, *133*, 11231–11239.
- [29] D. L. Ma, W. L. Wong, W. H. Chung, F. Y. Chan, P. K. So, T. S. Lai, Z. Y. Zhou, Y. C. Leung, K. Y. Wong, *Angew. Chem.* **2008**, *120*, 3795–3799; *Angew. Chem. Int. Ed.* **2008**, *47*, 3735–3739.
- [30] X. Wang, J. Jia, Z. Huang, M. Zhou, H. Fei, *Chem. Eur. J.* **2011**, *17*, 8028–8032.
- [31] Y. You, Y. Han, Y. M. Lee, S. Y. Park, W. Nam, S. J. Lippard, *J. Am. Chem. Soc.* **2011**, *133*, 11488–11491.
- [32] Y. You, S. Lee, T. Kim, K. Ohkubo, W. S. Chae, S. Fukuzumi, G. J. Jhon, W. Nam, S. J. Lippard, *J. Am. Chem. Soc.* **2011**, *133*, 18328–18342.
- [33] P. K. Lee, W. H. T. Law, H. W. Liu, K. K. W. Lo, *Inorg. Chem.* **2011**, *50*, 8570–8579.
- [34] P. Steunenberg, A. Ruggi, N. S. van den Berg, T. Buckle, J. Kuil, F. W. B. van Leeuwen, A. H. Velders, *Inorg. Chem.* **2012**, *51*, 2105–2114.
- [35] Q. Zhao, M. Yu, L. Shi, S. Liu, C. Li, M. Shi, Z. Zhou, C. Huang, F. Li, *Organometallics* **2010**, *29*, 1085–1091.
- [36] K. K. W. Lo, J. S. W. Chan, L. H. Lui, C. K. Chung, *Organometallics* **2004**, *23*, 3108–3116.
- [37] K. K. W. Lo, J. S. Y. Lau, *Inorg. Chem.* **2007**, *46*, 700–709.
- [38] K. K. W. Lo, K. Y. Zhang, S. K. Leung, M. C. Tang, *Angew. Chem.* **2008**, *120*, 2245–2248; *Angew. Chem. Int. Ed.* **2008**, *47*, 2213–2216.
- [39] K. K. W. Lo, K. Y. Zhang, C. K. Chung, K. Y. Kwok, *Chem. Eur. J.* **2007**, *13*, 7110–7120.
- [40] H. W. Liu, K. Y. Zhang, W. H. T. Law, K. K. W. Lo, *Organometallics* **2010**, *29*, 3474–3476.
- [41] J. S. Choi, A. J. Berdis, *Future Med. Chem.* **2012**, *4*, 1461–1478.
- [42] K. M. Smith, M. D. Slugoski, S. K. Loewen, A. M. Ng, S. Y. Yao, X. Z. Chen, E. Karpinski, C. E. Cass, S. A. Baldwin, J. D. Young, *J. Biol. Chem.* **2005**, *280*, 25436–25449.
- [43] A. J. Berdis, *Biochemistry* **2008**, *47*, 8253–8260.
- [44] W. Plunkett, V. Gandhi, *Hematol. Cell Ther.* **1996**, *38 Suppl 2*, S67–74.
- [45] V. Gandhi, W. Plunkett, *Clin. Pharmacokinet.* **2002**, *41*, 93–103.
- [46] W. B. Parker, J. A. Secrist 3rd, W. R. Waud, *Curr. Opin. Investig. Drugs* **2004**, *5*, 592–596.
- [47] V. Gandhi, W. Plunkett, *Curr. Opin. Oncol.* **2006**, *18*, 584–590.
- [48] D. S. Gestó, N. M. F. S. A. Cerqueira, P. A. Fernandes, M. J. Ramos, *Curr. Med. Chem.* **2012**, *19*, 1076–1087.
- [49] P. W. Marks, *Expert Rev. Anticancer Ther.* **2012**, *12*, 299–305.
- [50] C. A. Koczor, R. A. Torres, W. Lewis, *Expert Opin. Drug Metab. Toxicol.* **2012**, *8*, 665–676.
- [51] T. Robak, P. Robak, *Curr. Pharm. Des.* **2012**, *18*, 3373–3388.
- [52] Z. L. Johnson, C. G. Cheong, S. Y. Lee, *Nature* **2012**, *483*, 489–493.
- [53] For an alternative metalation, see: A. Maity, B. L. Anderson, N. De Ligonul, T. G. Gray, *Chem. Sci.* **2013**, *4*, 1175–1181.
- [54] For examples of cyclometalated iridium(III) complexes bearing one chelating triazole or triazolate ligand, see: a) S. Liu, P. Müller, M. K. Takase, T. M. Swager, *Inorg. Chem.* **2011**, *50*, 7598–7609; b) S. Zarnarini, M. Felici, G. Valenti, M. Marcaccio, L. Prodi, S. Bonacchi, P. Contreras Carballada, R. M. Williams, M. C. Feiters, R. J. M. Nolte, L. De Cola, F. Paolucci, *Chem. Eur. J.* **2011**, *17*, 4640–4647; c) B. Beyer, C. Ulbricht, D. Escudero, C. Friebe, A. Winter, L. González, U. S. Schubert, *Organometallics* **2009**, *28*, 5478–5488; d) E. Orselli, R. Q. Albuquerque, P. M. Fransen, R. Fröhlich, H. M. Janssen, L. De Cola, *J. Mater. Chem.* **2008**, *18*, 4579–4590.
- [55] J. M. Fernández Hernández, J. I. Beltrán, V. Lemaure, M. D. Gálvez López, C. H. Chien, F. Polo, E. Orselli, R. Fröhlich, J. Cornil, L. De Cola, *Inorg. Chem.* **2013**, *52*, 1812–1824.
- [56] K. N. Swanick, S. Ladouceur, E. Zysman Colman, Z. Ding, *Chem. Commun.* **2012**, *48*, 3179–3181.
- [57] A. B. Tamayo, B. D. Alleyne, P. I. Djurovich, S. Lamansky, I. Tsyba, N. N. Ho, R. Bau, M. E. Thompson, *J. Am. Chem. Soc.* **2003**, *125*, 7377–7387.
- [58] Y. You, W. Nam, *Chem. Soc. Rev.* **2012**, *41*, 7061–7084.
- [59] R. S. Mulliken, *J. Chem. Phys.* **1955**, *23*, 1833–1840.
- [60] L. Dagnino, L. L. Bennett, Jr., A. R. P. Paterson, *J. Biol. Chem.* **1991**, *266*, 6312–6317.
- [61] M. M. Gutierrez, K. M. Giacomini, *Biochim. Biophys. Acta* **1993**, *1149*, 202–208.
- [62] M. E. Schaner, J. Wang, L. Zhang, S. F. Su, K. M. Gerstin, K. M. Giacomini, *J. Pharmacol. Exp. Ther.* **1999**, *289*, 1487–1491.
- [63] K. M. King, V. L. Damaraju, M. F. Vickers, S. Y. Yao, T. Lang, T. E. Tackaberry, D. A. Mowles, A. M. Ng, J. D. Young, C. E. Cass, *Mol. Pharmacol.* **2006**, *69*, 346–353.
- [64] A. N. Elwi, V. L. Damaraju, M. L. Kuzma, D. A. Mowles, S. A. Baldwin, J. D. Young, M. B. Sawyer, C. E. Cass, *Am. J. Physiol. Renal Physiol.* **2009**, *296*, F1439–F1451.
- [65] H. Li, G. A. Smolen, L. F. Beers, L. Xia, W. Gerald, J. Wang, D. A. Haber, S. B. Lee, *PLoS One* **2008**, *3*, e2353.
- [66] D. A. Griffith, S. M. Jarvis, *Biochim. Biophys. Acta* **1996**, *1286*, 153–181.
- [67] M. Podgórska, K. Kocbuch, T. Pawelczyk, *Acta Biochim. Pol.* **2005**, *52*, 749–758.
- [68] V. Rolland, M. Kotera, J. Lhomme, *Synth. Commun.* **1997**, *27*, 3505–3511.
- [69] M. Nonoyama, *Bull. Chem. Soc. Jpn.* **1974**, *47*, 767–768.
- [70] E. Baranoff, B. F. E. Curchod, J. Frey, R. Scopelliti, F. Kessler, I. Tavernelli, U. Rothlisberger, M. Graetzel, M. K. Nazeeruddin, *Inorg. Chem.* **2012**, *51*, 215–224.
- [71] I. Shin, S. Yoon, J. I. Kim, J. Lee, T. H. Kim, H. Kim, *Electrochim. Acta* **2011**, *56*, 6219–6223.
- [72] T. Peng, Y. Yang, Y. Liu, D. Ma, Z. Hou, Y. Wang, *Chem. Commun.* **2011**, *47*, 3150–3152.
- [73] M. Schmitt, S. Qinghai, *Chem. Commun.* **2012**, *48*, 2707–2709.
- [74] S. Lamansky, P. Djurovich, D. Murphy, F. Abdel Razzaq, H. Lee, C. Adachi, P. E. Burrows, S. R. Forrest, M. E. Thompson, *J. Am. Chem. Soc.* **2001**, *123*, 4304–4312.
- [75] E. J. McLaurin, A. B. Greytak, M. G. Bawendi, D. G. Nocera, *J. Am. Chem. Soc.* **2009**, *131*, 12994–13001.
- [76] J. N. Demas, G. A. Crosby, *J. Phys. Chem.* **1971**, *75*, 991–1024.
- [77] S. Hamai, F. Hirayama, *J. Phys. Chem.* **1983**, *87*, 83–89.
- [78] Bruker Advanced X ray Solutions, SMART for WNT/2000 (Version 5.628), Bruker AXS, Inc., Madison, WI, **1997–2002**.
- [79] Bruker Advanced X ray Solutions, SAINT, Version 6.45, Bruker AXS, Inc., Madison, WI, **1997–2003**.
- [80] Bruker Advanced X ray Solutions, SHELXTL, Version 6.10, Bruker AXS, Inc., Madison, WI, **2000**.
- [81] Gaussian 09 (Revision A.02), M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A.

- Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2009**.
- [82] J. P. Perdew, K. Burke, M. Ernzerhof, *Phys. Rev. Lett.* **1996**, 77, 3865–3868.
- [83] S. Miertus, E. Scrocco, J. Tomasi, *Chem. Phys.* **1981**, 55, 117–129.
- [84] J. Tomasi, B. Mennucci, R. Cammi, *Chem. Rev.* **2005**, 105, 2999–3093.
- [85] E. Cancès, B. Mennucci, J. Tomasi, *J. Chem. Phys.* **1997**, 107, 3032–3041.
- [86] B. Mennucci, E. Cancès, J. Tomasi, *J. Phys. Chem. B* **1997**, 101, 10506–10517.
- [87] S. I. Gorelsky, AOMix: Program for Molecular Orbital Analysis, York University, Toronto, **1997**: <http://www.sg.chem.net>.
- [88] S. I. Gorelsky, A. B. P. Lever, *J. Organomet. Chem.* **2001**, 635, 187–196.